Shionogi & Co (4507) Price & Analysis

Compare

0 Followers

4507 Stock Chart & Stats

¥2697.00

-¥21.00(-0.94%)

At close: Jan 08 4:00 PM EST

¥2697.00

-¥21.00(-0.94%)

Day’s Range― - ―

52-Week Range¥2,100.00 - ¥2,955.00

Previous CloseN/A

Volume2.56M

Average Volume (3M)2.56M

Market Cap

¥2.56T

Enterprise Value¥2.00T

Total Cash (Recent Filing)¥233.86B

Total Debt (Recent Filing)¥22.70B

Price to Earnings (P/E)14.5

Beta0.54

Next Earnings

Jan 30, 2026

EPS Estimate

56.6

Next Dividend Ex-DateN/A

Dividend Yield2.22%

Share Statistics

EPS (TTM)51.93

Shares Outstanding889,632,200

10 Day Avg. Volume2,991,150

30 Day Avg. Volume2,559,626

Financial Highlights & Ratios

PEG Ratio1.47

Price to Book (P/B)1.40

Price to Sales (P/S)4.36

P/FCF Ratio10.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Acquisition BenefitsOne of the key benefits of JT Pharma acquisition is to gain additional small molecule-based drug discovery research capability and capacity.

Antibiotic GrowthOur antibiotic, Fetroja, has been growing strongly in the US, +38% YoY.

HIV Market PositionFor HIV long acting, the main market is treatment, not PreP, in which Cabenuva should enjoy competition-free till ~2030.

Bears Say

Clinical Trial OutcomesXocova is getting filed for prevention alone in the US while EMA is open for treatment as well despite the negative Ph3 outcome.

Financial PerformanceShionogi's FY24 top and bottom lines were a slight miss versus consensus and its guidance.

Guidance ExpectationsShionogi has set FY25 guidance lower than their original mid-term goal despite the acquisition of JT Group’s pharma division.

Shionogi & Co News

Shionogi Buys Global RADICAVA Rights in $2.5 Billion ALS Drug Deal to Build Rare Disease Platform

An announcement from Shionogi & Co ( ($JP:4507) ) is now available. Shionogi has agreed to acquire from...

20d ago

Shionogi Wins Japan Approval for Rapid-Acting Depression Drug ZURZUVAE

An announcement from Shionogi & Co ( ($JP:4507) ) is now available. Shionogi has received Japanese regulatory approval...

20d ago

Shionogi Completes Acquisition of Japan Tobacco’s Pharmaceutical Business

The latest update is out from Shionogi & Co ( ($JP:4507) ). Shionogi & Co., Ltd. has successfully...

1M ago

Shionogi Announces Corrections to Q2 2025 Financial Results

The latest update is out from Shionogi & Co ( ($JP:4507) ). Shionogi & Co., Ltd. announced corrections...

1M ago

Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion

Shionogi & Co ( ($SGIOF) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

Shionogi & Co. Adopts New Management Policies to Enhance Capital and Stock Awareness

The latest announcement is out from Shionogi & Co ( ($JP:4507) ). Shionogi & Co., Ltd. has announced...

3M ago

Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges

Shionogi & Co ( ($JP:4507) ) just unveiled an update. Shionogi & Co., Ltd. reported its financial results...

3M ago

Shionogi & Co. Reports Q2 2025 Financial Results and Strategic Expansion

An update from Shionogi & Co ( ($JP:4507) ) is now available. Shionogi & Co., Ltd. reported its...

3M ago

Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain

Shionogi & Co ( ($JP:4507) ) has provided an update. Shionogi & Co., Ltd. has announced a merger...

3M ago

SGIOF Earnings this Week: How Will it Perform?

Shionogi & Co (SGIOF) is scheduled to report 2nd quarter earnings on 10/27/2025, before the market opens. Regarding...

3M ago

4507 FAQ

What was Shionogi & Co’s price range in the past 12 months?

Shionogi & Co lowest stock price was ¥2100.00 and its highest was ¥2955.00 in the past 12 months.

What is Shionogi & Co’s market cap?

Shionogi & Co’s market cap is ¥2.56T.

When is Shionogi & Co’s upcoming earnings report date?

Shionogi & Co’s upcoming earnings report date is Jan 30, 2026 which is in 19 days.

How were Shionogi & Co’s earnings last quarter?

Shionogi & Co released its earnings results on Oct 27, 2025. The company reported ¥51.93 earnings per share for the quarter, beating the consensus estimate of ¥48.056 by ¥3.874.

Is Shionogi & Co overvalued?

According to Wall Street analysts Shionogi & Co’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shionogi & Co pay dividends?

Shionogi & Co pays a Semiannually dividend of ¥33 which represents an annual dividend yield of 2.22%. See more information on Shionogi & Co dividends here

What is Shionogi & Co’s EPS estimate?

Shionogi & Co’s EPS estimate is 56.6.

How many shares outstanding does Shionogi & Co have?

Shionogi & Co has 889,632,200 shares outstanding.

What happened to Shionogi & Co’s price movement after its last earnings report?

Shionogi & Co reported an EPS of ¥51.93 in its last earnings report, beating expectations of ¥48.056. Following the earnings report the stock price went up 1.637%.

Which hedge fund is a major shareholder of Shionogi & Co?

Currently, no hedge funds are holding shares in JP:4507

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Shionogi & Co

Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878, primarily engaged in the research, development, manufacturing, and marketing of pharmaceuticals. The company operates in various sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and diagnostic services. Shionogi's core products focus on infectious diseases, pain management, and central nervous system disorders, with a strong emphasis on innovation and the development of new therapies.

Shionogi & Co (4507) Earnings & Revenues

Historic Earnings Reports

4507 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1799":"¥1,799","2622":"¥2,622","2004.75":"¥2,004.8","2210.5":"¥2,210.5","2416.25":"¥2,416.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1800.154918674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥1.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1800.154918674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.80K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1799,2004.75,2210.5,2416.25,2622],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2621.5,2558.319609128769,2495.1392182575387,2431.958827386308,2368.778436515077,2305.598045643846,2242.4176547726156,2179.2372639013847,2116.056873030154,2052.876482158923,1989.6960912876925,1926.5157004164616,1863.3353095452308,{"y":1800.154918674,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2621.5,2419.846153846154,2218.1923076923076,2016.5384615384614,1814.8846153846152,1613.230769230769,1411.576923076923,1209.923076923077,1008.2692307692307,806.6153846153845,604.9615384615383,403.3076923076924,201.6538461538462,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2621.5,2558.319609128769,2495.1392182575387,2431.958827386308,2368.778436515077,2305.598045643846,2242.4176547726156,2179.2372639013847,2116.056873030154,2052.876482158923,1989.6960912876925,1926.5157004164616,1863.3353095452308,{"y":1800.154918674,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1995.923,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2039.675,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2160.401,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2229.526,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2183.767,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2257.913,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.338,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2379.869,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2516.637,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2527.006,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2555,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2580,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2621.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >